Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis

Exclusion Criteria

• •1\. Who are allergic to Arbidol.
• •2\. Patients with abnormal liver and kidney function (ALT and AST exceed the maximum limit of normal value by 1.5 times, and Cr exceeds the upper limit of normal value).
• •3\. Patients with abnormal ECG parameters and clinically significant (PR\>220ms, QRS\>120ms, QTc\>450ms) and bradycardia.
• •4\. Patients with severe asthma or acute asthma exacerbations.
• •5\. Patients with structural heart disease, severe hypertension (blood pressure greater than 180/110mmHg), diabetes, hyperthyroidism, malignant tumors, immunocompromise, and mental illness. Patients with structural heart disease, severe hypertension (blood pressure greater than 180/110mmHg), diabetes, hyperthyroidism, malignant tumors, immunocompromise, and mental illness.
• •6\. Patients with nasal polyps, severe deviated nasal septum, sinusitis, and hypertrophic rhinitis.
• •7\. Who have participated in other clinical studies within 3 months.
• •8\. Women are pregnant or lactating, in childbearing age with positive blood pregnancy test, or have pregnancy and lactation plans during the trial medication.
• •9\. Drug abuse and alcoholism.
• •10\. Who have received allergen-specific immunotherapy within 3 years.
• •11\. Positive infectious disease screening (hepatitis B surface antigen, hepatitis C antibody, AIDS antibody and treponema pallidum antibody).
• •12\. Who should not be included if there are other reasons in the opinion of the investigator.